For a woman of child‑bearing age with low‑risk gestational trophoblastic neoplasia (FIGO score ≤6), what is the efficacy of methotrexate versus dactinomycin (actinomycin D) as first‑line chemotherapy, and what factors should guide the choice between these agents?

Methotrexate vs. Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia

For low-risk GTN (FIGO score ≤6), either methotrexate with folinic acid (8-day regimen) or biweekly pulsed actinomycin D are acceptable first-line options with excellent outcomes, though the most recent high-quality evidence shows actinomycin D achieves higher primary cure rates (73% vs. 54%) with faster remission times. 1

Efficacy Comparison

Primary Complete Response Rates

The 2025 EOTTD-ESGO-GCIG-ISSTD guidelines report that both agents achieve 100% overall survival 1. However, there are important differences in primary response:

• Actinomycin D (biweekly pulsed): 70-94% primary complete response 1
• Methotrexate/folinic acid (adequately dosed): 88% complete response in the only randomized phase III trial using proper MTX dosing 1

Critical caveat: Earlier studies showing actinomycin D superiority predominantly used underdosed weekly intramuscular methotrexate regimens 1, 2. When comparing adequately dosed multiday methotrexate regimens (5-day or 8-day with folinic acid) to pulsed actinomycin D, the difference narrows considerably.

The most recent 2025 randomized trial (228 patients) demonstrated actinomycin D achieved significantly higher single-agent cure rates (72.8% vs. 54.4%, P=0.0038) with shorter median remission time (7.86 vs. 9.43 weeks, P=0.0296) 3. This represents the highest quality contemporary evidence.

Time to Remission

• Actinomycin D: Mean 2.9 months, requiring approximately 7 cycles 4
• Methotrexate (8-day): Mean 3.12 months, requiring approximately 10 cycles 4
• Combination MTX/Act-D: Mean 2.26 months, requiring 5.6 cycles (reserved for higher-risk cases within low-risk category) 4

Algorithm for Choosing Between Agents

Start with Methotrexate/Folinic Acid (8-day regimen) if:

• FIGO score 0-4 AND hCG <10,000 IU/L
• Patient prioritizes minimizing alopecia risk
• Concerns about nausea/vomiting tolerance
• Preference for intramuscular over intravenous administration

Dosing: Methotrexate 1.0-1.5 mg/kg IM on days 1,3,5,7, alternating with leucovorin 15 mg PO on days 2,4,6,8, repeated every 14 days 2

Start with Actinomycin D (biweekly pulsed) if:

• FIGO score 5-6 (higher within low-risk category) 4
• hCG ≥10,000 IU/L 4
• Patient prioritizes faster remission and fewer total cycles
• Methotrexate contraindications (pleural/peritoneal effusions, renal dysfunction, liver disease) 2
• Patient can tolerate alopecia risk

Dosing: 1.25 mg/m² IV (maximum 2 mg) every 14 days 1, 3

Avoid These Methotrexate Regimens:

• Weekly intramuscular methotrexate (30-50 mg/m²): Inferior efficacy, especially with FIGO scores >2 2
• Success rates drop to 40% (score 2-4) and 12% (score 5-6) 2

Toxicity Profile

Actinomycin D

• More common: Alopecia (significant concern for patients), nausea/vomiting (grade ≥2 more frequent) 2, 3
• Less common: Mucositis, liver enzyme elevation
• Severe adverse events: May be higher risk than methotrexate, though data are inconsistent 5

Methotrexate (8-day regimen)

• More common: Mucositis, liver enzyme elevation (ALT elevation more frequent) 2, 3
• Less common: Alopecia (minimal with proper regimens), nausea/vomiting
• Overall: Generally considered more favorable toxicity profile 2

Both agents show transient anti-Müllerian hormone reductions with recovery, suggesting preserved fertility potential 3.

Resistance and Second-Line Considerations

Defining Resistance

• hCG plateau over 3 consecutive cycles
• hCG rise over 2 consecutive cycles 2

Second-Line Strategy

• If started on methotrexate → switch to actinomycin D (75% complete response rate) 2
• If started on actinomycin D → switch to methotrexate or consider multiagent chemotherapy (EMA/CO) if hCG >1,000 IU/L 1
• All patients ultimately achieve cure with appropriate sequential therapy 1, 3

Critical Practice Points

1. Avoid weekly IM methotrexate: This underdosed regimen is responsible for much of the historical data showing methotrexate inferiority 1, 2

2. Consolidation is mandatory: Continue 2-3 cycles after hCG normalization regardless of agent used 1, 2

3. Monitor hCG every 1-2 weeks during treatment 1, 2

4. Consider secondary curettage: Can cure 40% of cases independent of endometrial thickness, but avoid multiple curettages to prevent scarring 1

5. Contraception required: Monthly hCG monitoring for 1 year post-remission with oral contraception preferred 2

6. For FIGO scores 5-6 with hCG ≥10,000: Consider combination MTX/Act-D upfront (5% failure rate vs. 21-37% for single agents) 4

The evidence supports either agent as acceptable first-line therapy, with the choice guided by FIGO score, hCG level, patient preferences regarding side effects, and institutional expertise. The 2025 data favor actinomycin D for superior primary cure rates, but adequately dosed methotrexate regimens remain highly effective with potentially better tolerability 1, 3.